Table 2.

Statistical findings shown as change from baseline at week 8 and 12

	+8 week follow-up						+12 week follow-up
	Probiotic		Placebo		ST		Probiotic		Placebo		ST
					p-value						p-value
Outcome parameter	x̅	Med	x̅	Med	tT	UT	x̅	Med	x̅	Med	tT	UT
GSRS	−0.04 ± 0.6	0 (−0.3–0.3)	−0.08 ± 0.6	−0.1 (−0.30.1)	0.63	0.18	−0.07 ± 0.6	0 (−0.4–0.2)	−0.08 ± 0.6	−0.1 (−0.4–0.2)	0.91	0.42
Diarrhea	−0.09 ± 0.7	0 (−0.7–0.3)	−0.05 ± 1.0	0 (−0.3–0.3)	0.63	0.89	−0.12 ± 0.9	0 (−0.3–0.3)	−0.05 ± 0.9	0 (−0.3–0)	0.61	0.52
Indigestion	−0.14 ± 0.9	−0.3 (−0.6–0.3)	−0.15 ± 0.8	0 (−0.5–0)	0.95	0.82	−0.14 ± 0.9	−0.1 (−0.5–0.3)	−0.13 ± 0.7	0 (−0.5–0.3)	0.94	0.89
Constipation	0.02 ± 1.1	0 (−0.7–0.7)	−0.03 ± 1.0	0 (−0.3–0.3)	0.76	0.46	−0.06 ± 1.1	0 (−0.7–0.3)	−0.10 ± 1.1	0 (−0.3−0.3)	0.82	0.99
Abdom. pain	−0.07 ± 0.6	0 (−0.3–0.2)	−0.07 ± 0.7	0 (−0.3–0.3)	0.94	0.92	−0.08 ± 0.7	0 (−0.3–0.3)	−0.09 ± 0.7	0 (−0.3–0.3)	0.95	0.86
Reflux	0.12 ± 0.7	0 (0–0)	−0.13 ± 0.6	0 (0–0)	0.02a	0.02a	−0.02 ± 0.7	0 (0–0)	−0.09 ± 0.5	0 (0–0)	0.45	0.33
EQ-5D
Index	0 ± 0.1	0 (0–0)	−0.01 ± 0.1	0 (−0.1–0)	0.35	0.23	0 ± 0.1	0 (0–0)	0 ± 0.1	0 (0–0)	0.87	0.79
VAS	1.89 ± 10.7	0 (−5–5)	0.60 ± 11.5	0 (−5–5)	0.44	0.76	2.88 ± 9.8	0 (−30–0)	3.47 ± 7.7	5 (0–10)	0.66	0.29
HADS	−0.32 ± 3.5	0 (−2–1)	−0.41 ± 2.9	0 (−2–1.3)	0.86	0.45	−0.18 ± 4.4	−0.5 (−2–1)	0.05 ± 5.2	0 (−2–2)	0.77	0.74
Depression	−0.01 ± 2.1	0 (−1–1)	−0.18 ± 1.9	0 (−1–0)	0.60	0.79	0.04 ± 2.2	0 (−1–1)	−0.01 ± 2.8	0 (−1–1)	0.89	0.91
Anxiety	−0.31 ± 2.1	0 (−1.3–1)	−0.23 ± 1.9	0 (−1–1)	0.79	0.54	−0.22 ± 2.7	0 (−2–0.13)	0.06 ± 3.0	0 (−1–1)	0.55	0.42
PSS	−0.41 ± 4.9	−1 (−3–2)	−0.24 ± 5.4	0 (−3.8–3)	0.82	0.59	−1.55 ± 4.8	−1 (−5–2)	−1.12 ± 4.4	−1 (−4–1.8)	0.57	0.58

x̅ = Mean ± SD

ST Significance testing between the two treatment groups

tT t-test

UT Mann-Whitney U-test

Med Median (IQR)

^asignificant at the 95 confidence level